The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Risk sentiment wavering: Before the potential ceasefire breach, the VIX index (a common gauge of investor fear) fell over 6.5 ...

Win Advisors Inc. recently acquired 3,241 shares of Amgen, investing roughly $1,010,000, as disclosed in their latest SEC ...

Microsoft is struggling to sell its Copilot AI assistant to corporations because many of their employees want ChatGPT.

Obesity late-comer Amgen announced full results from Part 1 of the Phase II study of MariTide (maridebart cafraglutide, ...

Amgen Inc. ( NASDAQ: AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & ...

A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and ...

A new trial has found that a weight loss drug taken monthly helps people lose 20 percent of their body weight. Weight loss medications such as Ozempic, Wegovy and Mounjaro have become popular and now ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

The S&P 500 advanced 1% on Monday, June 23, 2025, as investors weighed the potential severity and impact of Iran's ...